drugset / Trial / NCT00431041
Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).
Timeline
- Start
- 2006-12
- Primary completion
- 2008-02
- Completion
- 2008-02
Outcome
Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)
registry NUMBER Solifenacin: 24 participants NUMBER Oxybutynin IR: 53 participants analysis (superiority or other test); Solifenacin vs Oxybutynin IR; p <0.0001; Chi-squared NCT00431041 ↗
registry analysis (superiority or other test); Solifenacin vs Oxybutynin IR; p = 0.0010; Chi-squared; note: P-value represents overall comparison of severity of dry mouth. NCT00431041 ↗
Publications
- Background Herschorn S, Stothers L, Carlson K, Egerdie B, Gajewski JB, Pommerville P, Schulz J, Radomski S, Drutz H, Barkin J, Paradiso-Hardy F. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. J Urol. 2010 May;183(5):1892-8. doi: 10.1016/j.juro.2010.01.012. Epub 2010 Mar 29.
- Herschorn S, Pommerville P, Stothers L, Egerdie B, Gajewski J, Carlson K, Radomski S, Drutz H, Schulz J, Barkin J, Hirshberg E, Corcos J. Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (</= 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. Curr Med Res Opin. 2011 Feb;27(2):375-82. doi: 10.1185/03007995.2010.541433. Epub 2010 Dec 23.
- Herschorn S, Vicente C, Piwko C. Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder. J Med Econ. 2010;13(3):508-15. doi: 10.3111/13696998.2010.509244.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Oxybutynin | Small molecule | 5 mg | Oral |
| Subject | Solifenacin | Small molecule | 5 mg | Oral |